Who are RANCAD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Imjudo, Nivolumab in combination with Ipilimumab, tremelimumab (treme), APVO101, AK102, Fotemustine and Ipilimumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rancad.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RANCAD — Competitive Intelligence Brief

RANCAD (RANCAD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CTLA-4 inhibitor. Area: Oncology.

phase 3 CTLA-4 inhibitor CTLA-4 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

RANCAD (RANCAD) — TSH Biopharm Corporation Limited. RANCAD is a recombinant human anti-CTLA-4 monoclonal antibody that blocks the inhibitory checkpoint protein CTLA-4 to enhance anti-tumor immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RANCAD TARGET	RANCAD	TSH Biopharm Corporation Limited	phase 3	CTLA-4 inhibitor	CTLA-4
Imjudo	TREMELIMUMAB	AstraZeneca	marketed	CTLA-4-directed Blocking Antibody [EPC]	CTLA-4	2022-01-01
Nivolumab in combination with Ipilimumab	Nivolumab in combination with Ipilimumab	Bristol-Myers Squibb	marketed	Checkpoint inhibitor combination (PD-1 inhibitor + CTLA-4 inhibitor)	PD-1 and CTLA-4
tremelimumab (treme)	tremelimumab (treme)	AstraZeneca	marketed	CTLA-4 inhibitor	CTLA-4
APVO101	APVO101	Medexus Pharma, Inc.	phase 3	Dual checkpoint inhibitor	PD-1 and CTLA-4
AK102	AK102	Akeso	phase 3	Bispecific checkpoint inhibitor	PD-1 and CTLA-4
Fotemustine and Ipilimumab	Fotemustine and Ipilimumab	Italian Network for Tumor Biotherapy Foundation	phase 3	Chemotherapy + immune checkpoint inhibitor combination	DNA alkylation (fotemustine); CTLA-4 (ipilimumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CTLA-4 inhibitor class)

AstraZeneca · 3 drugs in this class
Federation Francophone de Cancerologie Digestive · 1 drug in this class
Providence Health & Services · 1 drug in this class
Shanghai Henlius Biotech · 1 drug in this class
TSH Biopharm Corporation Limited · 1 drug in this class
Takara Bio Inc. · 1 drug in this class
The Netherlands Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RANCAD — Competitive Intelligence Brief. https://druglandscape.com/ci/rancad. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab